cotransin | 863753-73-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: cotransin
• 英文别名: (3S,6S,9S,12S,15S,18S,21R)-9-benzyl-3,4,10,16,21-pentamethyl-6,12,15,18-tetrakis(2-methylpropyl)-1-oxa-4,7,10,13,16,19-hexazacyclohenicosane-2,5,8,11,14,17,20-heptone
• CAS: 863753-73-5
• 化学式: C₄₂H₆₈N₆O₈
• 分子量: 785.037
• InChiKey: LTYNXERAWVCPAH-OHRKNAERSA-N

物化性质

• 沸点：
  1010.9±65.0 °C(Predicted)
• 密度：
  1.029±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  56
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  175
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  cotransin 在 哌啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 生成
  参考文献：
  名称：

  Solid-Phase Synthesis of a Cyclodepsipeptide: Cotransin

  摘要：

  The first solid-phase synthesis of cotransin-a cyclic depsipeptide having high pharmacological potential-was achieved, by a proper choice of coupling reagents and use of either TBAF or DBU for Fmoc removal to suppress the otherwise dominating, sequence-derived diketopiperazine formation. Starting the assembly from C-terminal lactic acid allowed fast and epimerization-free cyclization in solution. Novel conditions for orthogonal use of the Fmoc/Bsmoc-protection system were discovered, and an unexpected nucleophilic behavior of DBU was observed.

  DOI：

  10.1021/ol800855p
• 作为产物：
  描述：

  H-Leu-N(Me)Leu-Leu-N(Me)Phe-Leu-N(Me)Ala-D-OAla-OH 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 以70%的产率得到cotransin
  参考文献：
  名称：

  Solid-Phase Synthesis of a Cyclodepsipeptide: Cotransin

  摘要：

  The first solid-phase synthesis of cotransin-a cyclic depsipeptide having high pharmacological potential-was achieved, by a proper choice of coupling reagents and use of either TBAF or DBU for Fmoc removal to suppress the otherwise dominating, sequence-derived diketopiperazine formation. Starting the assembly from C-terminal lactic acid allowed fast and epimerization-free cyclization in solution. Novel conditions for orthogonal use of the Fmoc/Bsmoc-protection system were discovered, and an unexpected nucleophilic behavior of DBU was observed.

  DOI：

  10.1021/ol800855p

文献信息

• [EN] CDP PROTEIN SECRETION INHIBITORS<br/>[FR] INHIBITEURS DE SÉCRÉTION DE PROTÉINE CDP
  申请人：KEZAR LIFE SCIENCES

  公开号：WO2019191527A1

  公开（公告）日：2019-10-03

  rovided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61. Also provided are compositions of the inhibitor compounds, and methods of using these inhibitors. The compounds disclosed herein can be used, e.g., for the treatment of cancer, arthritis, and/or inflammation.

  根据您的要求，以下是翻译结果： "本文提供了抑制蛋白质分泌的化合物，例如通过抑制Sec61。还提供了抑制剂化合物的组合物和使用这些抑制剂的方法。此处披露的化合物可用于治疗癌症、关节炎和/或炎症。"
• CDP protein secretion inhibitors
  申请人：KEZAR LIFE SCIENCES

  公开号：US11339193B2

  公开（公告）日：2022-05-24

  Provided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61. Also provided are compositions of the inhibitor compounds, and methods of using these inhibitors. The compounds disclosed herein can be used, e.g., for the treatment of cancer, arthritis, and/or inflammation.

  本文提供了抑制蛋白质分泌的化合物，例如通过抑制 Sec61。还提供了抑制剂化合物的组合物以及使用这些抑制剂的方法。本文公开的化合物可用于治疗癌症、关节炎和/或炎症等。
• CDP PROTEIN SECRETION INHIBITORS
  申请人：KEZAR LIFE SCIENCES

  公开号：US20210017233A1

  公开（公告）日：2021-01-21

  Provided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61. Also provided are compositions of the inhibitor compounds, and methods of using these inhibitors. The compounds disclosed herein can be used, e.g., for the treatment of cancer, arthritis, and/or inflammation.